Key Highlights

  • ICU rose about 5.1% at last closing to near $3.10, valuing the company at roughly $13.7 million.
  • Second-quarter net Revenue grew 82% year over year to about $0.6 million as its pediatric hospital base expanded to 20 facilities.
  • SeaStar secured dedicated ICD-10-PCS billing codes for QUELIMMUNE, effective October 1, 2026.
  • Its pivotal NEUTRALIZE-AKI adult trial had enrolled 223 of 339 targeted patients as of the update.

SeaStar Medical Holding Corporation (NASDAQ:ICU) gave investors a modest reason to cheer, with its shares climbing about 5% in a recent session. The Nasdaq-listed maker of a novel kidney-injury therapy, ticker ICU, has been building a commercial track record for QUELIMMUNE, its treatment for pediatric acute kidney injury, while pushing a larger adult study toward the finish line. For a micro-cap in the medical-device space, steady clinical and commercial progress has been enough to keep the stock in the conversation this September.

Company and Latest Development

SeaStar Medical develops the Selective Cytopheretic Device (SCD), an immunomodulation technology that targets overactive immune cells in critically ill patients. Its first commercial product, QUELIMMUNE, is approved for certain children with acute kidney injury and is being adopted across U.S. pediatric hospitals. The most recent verified update came with second-quarter 2026 results, reported in August: net revenue of about $0.6 million, an 82% increase from roughly $0.3 million a year earlier, as the company expanded its pediatric hospital customer base to 20 facilities. Gross Margin reached roughly 91%, though the company posted a net loss of about $3.7 million.

What Is Driving Attention Around ICU?

The roughly 5% single-session gain does not trace to one confirmed, same-day catalyst that can be independently verified; for a micro-cap with limited float, moves of that size are common on light news. The broader story, however, is tangible progress. SeaStar secured dedicated ICD-10-PCS billing codes effective October 1, 2026, which should ease hospital reimbursement for its therapy, and its pivotal NEUTRALIZE-AKI trial in adults had enrolled 223 of 339 patients, with completion targeted for late 2026 or early 2027. Earlier in the year, expanded SAVE Registry data showed encouraging pediatric survival figures with no device-related adverse events.

Key Numbers and Company Position

Verified second-quarter 2026 figures include net revenue of about $0.6 million, up 82% year over year, a gross margin near 91%, and a net loss of roughly $3.7 million, or about $0.91 per share. Cash stood at approximately $7.0 million, down from about $12.0 million at the end of 2025. Recent market data placed the shares near $3.10 with a market Capitalization of roughly $13.7 million. The adult trial's enrollment count, 223 of 339 patients, is a key operational metric.

What Could Come Next?

Several catalysts lie ahead. Completion of NEUTRALIZE-AKI enrollment and eventual topline data would be pivotal, potentially opening a far larger adult AKI market. The October 1 activation of ICD-10-PCS codes could support broader QUELIMMUNE adoption and reimbursement, and continued additions to the pediatric hospital customer base would reinforce the commercial ramp. Investors may also be watching quarterly revenue trends and any financing steps given the declining cash balance.

Risks to Watch

SeaStar's cash position, near $7.0 million against ongoing losses, points to likely future financing needs and potential dilution. The adult NEUTRALIZE-AKI trial carries clinical and regulatory risk; a disappointing readout would remove the company's biggest growth catalyst. Commercial adoption of QUELIMMUNE is still early and revenue remains small relative to expenses. As a micro-cap, the shares can be volatile and sensitive to thin liquidity, and any reimbursement or competitive shifts could weigh on the outlook.

Early Commercial Traction Ahead of an Adult Trial

SeaStar Medical is pairing early commercial traction for QUELIMMUNE with a pivotal adult trial that could define its future. Investors may want to monitor NEUTRALIZE-AKI progress, QUELIMMUNE adoption and reimbursement, and the company's cash runway, while remaining mindful of the dilution and clinical risks common to small, unprofitable medical-device firms.